Literature DB >> 22402292

TACE with or without systemic therapy?

Jean-François Dufour.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22402292     DOI： 10.1016/j.jhep.2012.02.011

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  7 in total

Review 1.  Combination of local transcatheter arterial chemoembolization and systemic anti-angiogenic therapy for unresectable hepatocellular carcinoma.

Authors:  Eleni Liapi; Jean-Francois H Geschwind
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

Review 2.  Current systemic treatment of hepatocellular carcinoma: A review of the literature.

Authors:  Kai-Wen Chen; Tzu-Ming Ou; Chin-Wen Hsu; Chi-Ting Horng; Ching-Chang Lee; Yuh-Yuan Tsai; Chi-Chang Tsai; Yi-Sheng Liou; Chen-Chieh Yang; Chao-Wen Hsueh; Wu-Hsien Kuo
Journal:  World J Hepatol       Date:  2015-06-08

3.  CKAP4 inhibited growth and metastasis of hepatocellular carcinoma through regulating EGFR signaling.

Authors:  Shuang-Xi Li; Li-Juan Liu; Li-Wei Dong; Hong-Guang Shi; Yu-Fei Pan; Ye-Xiong Tan; Jian Zhang; Bo Zhang; Zhi-Wen Ding; Tian-Yi Jiang; He-Ping Hu; Hong-Yang Wang
Journal:  Tumour Biol       Date:  2014-05-18

4.  Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study.

Authors:  Zhexuan Wang; Enxin Wang; Wei Bai; Dongdong Xia; Rong Ding; Jiaping Li; Qiuhe Wang; Lei Liu; Junhui Sun; Wei Mu; Hui Zhao; Xingnan Pan; Guoliang Shao; Xiaoli Zhu; Guowen Yin; Haibin Shi; Jianbing Wu; Zhengyu Lin; Shufa Yang; Jueshi Liu; Wenhui Wang; Xu Zhu; Yong Lv; Jing Li; Hui Chen; Wenjun Wang; Kai Li; Xulong Yuan; Tanlei Yu; Jie Yuan; Xiaomei Li; Jing Niu; Zhanxin Yin; Jielai Xia; Daiming Fan; Guohong Han
Journal:  Liver Cancer       Date:  2020-02-19       Impact factor: 11.740

Review 5.  Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review.

Authors:  Rodolfo Sacco; Gherardo Tapete; Natalia Simonetti; Rossella Sellitri; Veronica Natali; Sara Melissari; Giuseppe Cabibbo; Lilia Biscaglia; Giampaolo Bresci; Luca Giacomelli
Journal:  J Hepatocell Carcinoma       Date:  2017-07-27

6.  Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation.

Authors:  Liang Yin; Kai-Cai Liu; Wei-Fu Lv; Shao-Bao Xu; Dong Lu; Chun-Ze Zhou; De-Lei Cheng; Zong-Gen Gao; Chang-Sheng Shi; Ming-Xue Su
Journal:  Drug Des Devel Ther       Date:  2022-09-30       Impact factor: 4.319

7.  Radiologic Response Combined with Dermatologic Toxicities is the Most Robust Predictor of Survival Benefits in Patients with Inoperable Hepatocellular Carcinoma After Transarterial Chemoembolization Plus Sorafenib Therapy.

Authors:  Zhiqiu Ye; Zhizhen Deng; Suxiang Jiang; Tang Wang; Long Liu; Kuiming Jiang; Yingqiang Zhang
Journal:  Cardiovasc Intervent Radiol       Date:  2021-05-04       Impact factor: 2.740
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.